CTNM Healthcare

Contineum Therapeutics, Inc.

$9.69+1.36%

Price as of close on Nov 3, 2026 · Financials updated Oct 1, 2026

Basics

Sector: Healthcare
Industry: Biotechnology
Country: United States
Market cap: 364.5M USD
Enterprise value: 134.6M USD
Full-time employees: 51

Overall health

Strength: lower risk than most peers: more short-term liquidity and less debt relative to equitylower risk: more liquidity and less debt vs equity
Drawback: less profitable than most peersless profitable than peers
Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings
Not enough data: growth

Would rank #815 of 1,157 fully scored healthcare companies (bottom 30%)

Partial overall score — 3/4 categories available.

See how it ranks against its peers

Worth knowing

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.
Relative to its free cash flow, Contineum Therapeutics looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.
Not profitable yet. Reported a loss in the 12 months to June 2026.
Contineum Therapeutics reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.

StockQuotient Score

41/ 100

Oct 5 41 → Nov 4 41

Valuation

Is the price right?

8/100

Weak

3/3 inputs reported · High confidence

Why

Weaker than most peers on:

▼ Earnings yield
▼ EBITDA yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-15.9%

SEC filings · 12 months to Jun 2026Negative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yield-49.0%

Yahoo Finance fallback · SEC enterprise value unavailable (debt or EBITDA not reported in standard form) · trailing 12 monthsNegative (a loss or cash outflow), so it counts as zero whatever the share price50% base weight · Z-score -1.00Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield-14.7%

SEC filings · 12 months to Jun 2026 · operating cash flow − capital spendingNegative (a loss or cash outflow), so it counts as zero whatever the share price20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield66.0%

SEC filings · latest balance sheetReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

Insufficient data

Insufficient data: 1 of 3 inputs reported (at least 2 needed). We leave it blank rather than fill the gap with a made-up middle value.

Profitability

Does it earn well?

21/100

Weak

2/3 inputs reported · Partial data

Why

Weaker than most peers on:

▼ ROA
▼ ROIC

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating marginUnavailable

Missing · left out of the score · no sector data, so not countedNot counted · remaining weights rescaledSector median: 0.0706 · MAD: 0.1217

Return on assets-23.0%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -4.59Sector median: 0.0166 · MAD: 0.0537

Return on invested capital-23.3%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -2.79Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin0.0%

Yahoo Finance fallback · SEC figure unavailable or out of date · trailing 12 monthsReported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity-24.0%

SEC filings · 12 months to Jun 2026Reported valueInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Lower

Lower relative risk

3/3 inputs reported · High confidence

Why

Stronger than most peers on:

▲ Current ratio
▲ Debt / equity

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta0.75

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score -0.36Sector median: 0.6250 · MAD: 0.3380

Current ratio37.17×

SEC filings · latest balance sheetOutlier capped at sector 5th/95th percentile33% base weight · Z-score 11.07Sector median: 2.5860 · MAD: 1.3850

Debt / equity0.03×

Yahoo Finance fallback · no standard SEC debt tagReported value33% base weight · Z-score 0.95Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about Contineum Therapeutics

Is Contineum Therapeutics getting weaker?: A comparison of its latest SEC filing with the previous one isn't available yet. Its overall score is unchanged at 41/100 since Oct 28, 2026.
How is Contineum Therapeutics valued vs its peers?: Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -15.9% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -15.9% vs peers 1.5% (weaker than 100% of peers).
Is Contineum Therapeutics growing?: Insufficient data: 1 of 3 inputs reported (at least 2 needed).
How profitable is Contineum Therapeutics?: Less profitable than most of its peers. Profitability scores 21/100 against 1,393 healthcare peers. Return on assets -23.0% vs a peer median of 1.7% (weaker than 82% of peers).Return on assets -23.0% vs peers 1.7% (weaker than 82% of peers).
How risky is Contineum Therapeutics?: Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 37.17× vs a peer median of 2.59× (stronger than 95% of peers).Current ratio 37.17× vs peers 2.59× (stronger than 95% of peers). A relative measure, not a bankruptcy probability.

Industry valuation context

Industry: Biotechnology · 132 companies

Valuations in Biotechnology are within their usual range since 2016.

48% of months since 2016 were valued lower than now.
22% of companies are in the most expensive fifth of their own price-to-sales history.
Median price-to-sales is +530% vs the whole market, against a usual +637%.

2016Shaded: most expensive fifth of its range2026

Earnings-based measures are left out for now because many companies in Biotechnology are losing money.

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2023	FY 2024	FY 2025	Change
Operating margin	32.2%	—	—	—
Net margin	45.4%	—	—	—
Return on assets (ROA)	17.4%	-19.9%	-21.7%	▼ 1.8 pts
Return on equity (ROE)	—	-21.3%	-23.0%	▼ 1.6 pts
Free cash flow margin	37.9%	—	—	—
Current ratio	23.29×	20.69×	27.50×	▲ 33%
Interest coverage	77.29×	—	—	—

CTNM price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Strength: lower risk than most peers: more short-term liquidity and less debt relative to equitylower risk: more liquidity and less debt vs equity

Drawback: less profitable than most peersless profitable than peers

Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings

Not enough data: growth

Would rank #815 of 1,157 fully scored healthcare companies (bottom 30%)

Partial overall score — 3/4 categories available.

See how it ranks against its peers

Worth knowing

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.

Relative to its free cash flow, Contineum Therapeutics looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

Not profitable yet. Reported a loss in the 12 months to June 2026.

Contineum Therapeutics reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.

Questions investors ask about Contineum Therapeutics

Is Contineum Therapeutics getting weaker?

A comparison of its latest SEC filing with the previous one isn't available yet. Its overall score is unchanged at 41/100 since Oct 28, 2026.

How is Contineum Therapeutics valued vs its peers?

Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -15.9% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -15.9% vs peers 1.5% (weaker than 100% of peers).

Is Contineum Therapeutics growing?

Insufficient data: 1 of 3 inputs reported (at least 2 needed).

How profitable is Contineum Therapeutics?

Less profitable than most of its peers. Profitability scores 21/100 against 1,393 healthcare peers. Return on assets -23.0% vs a peer median of 1.7% (weaker than 82% of peers).Return on assets -23.0% vs peers 1.7% (weaker than 82% of peers).

How risky is Contineum Therapeutics?

Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 37.17× vs a peer median of 2.59× (stronger than 95% of peers).Current ratio 37.17× vs peers 2.59× (stronger than 95% of peers). A relative measure, not a bankruptcy probability.

Key ratios

FY 2023

FY 2024

FY 2025

Change

Operating margin

32.2%

—

Net margin

45.4%

—

Return on assets (ROA)

17.4%

-19.9%

-21.7%

▼ 1.8 pts

Return on equity (ROE)

—

-21.3%

-23.0%

▼ 1.6 pts

Free cash flow margin

37.9%

—

Current ratio

23.29×

20.69×

27.50×

▲ 33%

Interest coverage

77.29×

—